From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
GZ22-4 is a near-infrared (NIR) fluorescent probe. GZ22-4 shows high affinity for carbonicanhydraseIX (CAIX), with a Kd of 0.2 nM. GZ22-4 can be used for the research of visualize CAIX-positive tumors .
hCAIX/XII-IN-6 is an orally active carbonicanhydrase (CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA) .
Carbonicanhydrase inhibitor 24 (Compound 11) is a human carbonicanhydrase(carbonicanhydrase) inhibitor. Ki values of Carbonicanhydrase inhibitor 24 for hCAs IX and XII were 10.7 and 7.5 nM, respectively .
Carbonicanhydrase inhibitor 20 (compound 11) is an inhibitor of piperazinosulfonamide carbonicanhydrase(CarbonicAnhydrase). The Ki of Carbonicanhydrase inhibitor 20 for hCA I, hCA II, hCA IX, and hCA XII are 47.6 nM, 36.5 nM, 8.3 nM, and 2.7 nM respectively .
Carbonicanhydrase inhibitor 11 (compound VI) is a potent, selective carbonicanhydrase inhibitor. Carbonicanhydrase inhibitor 11 shows Ki values of 40, 39, 200 and 900 nM against CA II, IX, and XII, respectively .
Carbonicanhydrase inhibitor 21 (Compound 5h) is a selective carbonicanhydrase (hCA IX) inhibitor, with a Ki of 15.1 nM, and is highly selective against other investigated isoform. Carbonicanhydrase inhibitor 21 can be used for anticancer research .
Carbonicanhydrase inhibitor 9 is a potent carbonicanhydrase (CA) inhibitor with Kis of 56.4 and 56.9 nM for hCA II and IX, respectively. Antiproliferative activity .
Carbonicanhydrase inhibitor 10 is a potent hCA IX inhibitor with a Ki value of 6.2 nM. Carbonicanhydrase inhibitor 10 exhibits anti-proliferative activity against MCF-7 cancer cell line with an IC50 of 11.9 μM. Carbonicanhydrase inhibitor 10 can be used for cancer research .
Carbonicanhydrase inhibitor 18 (Compound 9) is a human carbonicanhydrase (hCA) isoform inhibitor, with Kis of 604.8, 333.6, 1.9 and 6.7 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonicanhydrase inhibitor 18 can be used for the research of cancer .
Carbonicanhydrase inhibitor 5 is a potent and selective human carbonicanhydrase (hCA) inhibitor with IC50s of 42.9, 47,6 and 6.7 nM for hCA II, hCA IX and hCA XII, respectively .
Carbonicanhydrase inhibitor 14 (Compound 8b) is a carbonicanhydrase (CA) inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonicanhydrase inhibitor 14 can also inhibit CDK2 with an IC50 of 20.3 μM. Carbonicanhydrase inhibitor 14 shows antitumor activity .
Acetazolamide is a carbonicanhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities .
Acetazolamide sodium is a carbonicanhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide sodium has diuretic, antihypertensive and anti-gonococcal activities .
ALP/Carbonicanhydrase-IN-1 (Compound 1e) is a dual carbonicanhydrase (CA) and alkaline phosphatase (ALP) inhibitor. ALP/Carbonicanhydrase-IN-1 shows IC50 values of 0.44 µM, 1.61 µM, 0.51 µM, and 0.107 µM for CA-II, CA-IX, CA-XII, and ALP, respectively .
Carbonicanhydrase inhibitor 7 (compound 5b) is a potent inhibitor of human carbonicanhydrase (hCA), with Kis of 6.5 nM, 7.1 nM, 72.1 nM, and 255.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .
Carbonicanhydrase inhibitor 6 (compound 9b) is a potent inhibitor of human carbonicanhydrase (hCA), with Kis of 9.7 nM, 35.2 nM, 88.5 nM, and 91.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .
hCAI/II-IN-9 is a carbonicanhydrase inhibitor with inhibitory activity against human carbonicanhydrase isoforms I, II, IX, and XII. The inhibition constants (Ki) of hCAI/II-IN-9 for hCA I are in the range of 7.9-894 nM, for hCA II are in the range of 7.5-1645 nM, for hCA IX are in the range of 5.0-240 nM, and for hCA XII are in the range of 0.47-2.83 nM. hCAI/II-IN-9 may have potential applications in inhibiting a variety of pathologies involving these carbonicanhydrase isoforms .
Enpp/Carbonicanhydrase-IN-1 (compound 1e) is a potent Enpp and carbonicanhydrase inhibitor with IC50s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonicanhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonicanhydrase-IN-1 induces Apoptosis .
Enpp/Carbonicanhydrase-IN-2 (compound 1i) is a potent Enpp and carbonicanhydrase inhibitor with IC50s of 1.13, 1.07, 0.74, 0.33, 0.68 for NPP1, NPP2, NPP3, CA-IX, CA-XII respectively. Enpp/Carbonicanhydrase-IN-2 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonicanhydrase-IN-2 induces Apoptosis .
Acetazolamide- 13C2,d3 is the 13C- and deuterium labeled Acetazolamide. Acetazolamide is a carbonicanhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX[1]. Diuretic effects[4].
hCAIX-IN-20 (compound APBS-5m) is a potent inhibitor of carbonicanhydraseIX (hCA IX), with the Ki of 2.7 nM. hCAIX-IN-20 plays an important role in cancer research .
Acetazolamide (Standard) is the analytical standard of Acetazolamide. This product is intended for research and analytical applications. Acetazolamide is a carbonicanhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities .
hCA IX-IN-1 (Compound 6f) is a human carbonicanhydrase (hCA) inhibitor with Ki values of 331.4, 28.4, 9.4 and 17.8 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-1 shows anticancer activity .
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonicanhydraseIX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
hCA XII/II/IX-IN-1 (Compound 3) is a potent human carbonicanhydrase (hCA) inhibitor with IC50 values of 2.6, 0.004, 0.005 and 0.001 μM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA XII/II/IX-IN-1 shows anticancer activity .
hCAII-IN-3 (Compound 16) is a human carbonicanhydrase (hCA) inhibitor with Ki values of 403.8, 5.1, 10.2 and 5.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-2 shows anticancer activity .
hCAII-IN-7 (Compound R-13) is a potent human carbonicanhydrase(hCA) inhibitor with Kis of 60.7, 320.7, 2298, and 35.2 nM for hCA I, II, IV and IX, respectively .
hCAIX-IN-11 (Compound 5d) is a selective carbonicanhydraseIX and XII inhibitor with Ki s of 32.7 and 623.5 nM for hCA IX and hCA XII, respectively. hCA IX and hCA XII are transmembrane isoforms which have been characterized as biomarkers for several types of tumors. The hCA XII assists in maintenance of acid-base homoeostasis in normal as well as tumor cells .
hCAIX-IN-10 (Compound 6i) is a selective carbonicanhydraseIX and XII inhibitor with Ki s of 61.5 and 586.8 nM for hCA IX and hCA XII, respectively. hCA IX and hCA XII are transmembrane isoforms which have been characterized as biomarkers for several types of tumors. The hCA XII assists in maintenance of acid-base homoeostasis in normal as well as tumor cells .
hCAII-IN-1 (compound 7f) is a potent and selective inhibitor of carbonicanhydrase (CA II/IX) with Kis of 1.2 and 113.6 nM, respectively. hCAII-IN-1 has the potential for the research of cancer diseases .
hCAII-IN-3 (compound 7e) is a potent and selective inhibitor of carbonicanhydrase (CA II/IX) with Kis of 124.2 and 30.5 nM, respectively. hCAII-IN-3 has the potential for the research of cancer diseases .
hCAIX/XII-IN-9 (compound 8) is a potent carbonicanhydrase (CA) inhibitor with Ki values of 1658 nM, 184.8 nM, 8.9 nM, 64.8 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively .
hCAII-IN-2 (Compound 11f) is a cytosolic human carbonicanhydrase (hCA) inhibitor with Ki values of 261.4, 3.8, 19.6 and 45.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively .
U-104 (SLC-0111) is a potent carbonicanhydrase (CA) inhibitor for CA IX and CA XII with Ki values of 45.1 nM and 4.5 nM, respectively. U-104 shows a significant delay in tumor growth in mice model .
hCAXII-IN-2 (compound 5i) is a potent human carbonicanhydrase XII (hCA XII) and hCA IX inhibitor with Ki values of 84.2 nM and 268.5 nM, respectively. hCAXII-IN-2 shows less active against hCA I and hCA II .
hCAIX/XII-IN-10 (compound DK-8) is a carbonicanhydrase inhibitor. hCAIX/XII-IN-10 has potent inhibitory activity against tumor-associated membrane-bound isoforms hCA IX and XII, with Ki values of 32.5 nM and 29.2 nM .
DTP348 is an inhibitor for carbonicanhydraseIX with a Ki of 8.3 nM in vitro and an IC50 of 19.26 μM in Xenopus oocytes. DTP348 exhibits slight toxicity in zebrafish embryos with LD50 of 3.5 mM. DTP348 can be used in the anti-cancer research .
hCAII-IN-9 is a potent carbonicanhydrase inhibitor with IC50s of 1.18 μM (hCA II), 0.17 μM (hCA IX), and 2.99 μM (hCA XII), respectively. hCAII-IN-9 has no blood-brain barrier permeability .
Furagin (Standard) is the analytical standard of Furagin. This product is intended for research and analytical applications. Furagin (Furazidine) is an analogue of Nitrofurantoin (HY-A0090) and has antibacterial activity. Furagin also inhibits human carbonicanhydrases (Kis: 260 and 57 nM for hCA IX and XII, respectively) .
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual CarbonicAnhydrase(CA) IX/XII with Ki values of 4.7 nM and 8.3 nM for hCA XII and hCA IX, respectively. hCA/VEGFR-2-IN-1 (compound 13a) is a potent VEGFR-2 inhibitor with IC50 values 26.3 nM. hCA/VEGFR-2-IN-1 has anticancer activity .
hCAIX/XII-IN-8 (compound 3g) is a potent human (carbonicanhydrase) CA IX and XII inhibitor, with Ki values of 8.5 and 6.7 nM, respectively. hCAIX/XII-IN-8 shows particularly strong inhibitory activity against the tumor-associated membrane-bound isoforms, hCA IX and XII, while maintaining a high selectivity ratio over cytosolic off-target isoforms hCA I and II .
Anti-inflammatory agent 67 (compound 7a) is a dual inhibitor of carbonicanhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), and has anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 67 has IC50s of 10.4 μM and 50 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 67 binding to different isoforms of carbonicanhydrase are 48.3 nM (CA I), 42.2 nM (CA II), 52.3 nM (CA IX), and 13.3 nM (CA XII) .
Anti-inflammatory agent 68 (compound 7b) is a dual inhibitor of carbonicanhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), with anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 68 has IC50s of 12.6 μM and 60 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 68 binding to different isoforms of carbonicanhydrase are 52.6 nM (CA I), 79.1 nM (CA II), 58.1 nM (CA IX), and 17.2 nM (CA XII) .
CAIX Inhibitor S4 is a potent and selective inhibitor of carbonicanhydraseIX/XII (CA IX/XII), with a Ki of 7 nM and 2 nM, respectively. CAIX Inhibitor S4 also inhibits CA II and CA I (Ki=546 and 5600 nM, respectively). CAIX Inhibitor S4 can inhibit the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth .
hCAIX-IN-23 (Compound 27) is a human carbonicanhydrase (hCA) inhibitor with Ki values of 10.4 and 8.5 nM for hCA IX and hCA XII, respectively. In addition to inhibiting hCA activity, hCAIX-IN-23 releases NO, exhibiting dual antitumor activity. hCAIX-IN-23 induces apoptosis by regulating mitochondrial caspase activity and the ferroptosis pathway (ferroptosis) through the downregulation of hCA IX and iron-regulatory protein expression. hCAIX-IN-23 is useful for renal cancer research .
hCAII-IN-6 (Compound S-13) is a potent human carbonicanhydrase II (hCA II) inhibitor with a Ki of 4.4 nM. hCAII-IN-6 also inhibits other hCAs isoforms I, IV and IX, with Ki values of 9.2 nM, 480.2 nM and 14.7 nM, respectively. hCAII-IN-6 can be used for glaucoma research .
CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonicanhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .
CA IX-IN-2 (Compound 9o) is an inhibitor for carbonicanhydrase (CA), that inhibits CA IX, CA XII and CA II with an IC50 of 5.6, 7.4 and 430 nM, respectively. CA IX-IN-2 inhibits the proliferation of cancer cell HCT-116, SW480, MDA-MB 231 and MCF-7, with IC50s of 14.63-29.33 μM. CA IX-IN-2 intercalates DNA, arrests cell cycle at G1/S phase, and induces apoptosis in MDA-MB-231. CA IX-IN-2 affects the mitochondrial membrane potential (MMP), increases the intracellular ROS levels, causes mitochondrial damage, and inhibits the cell migration of MDA-MB-231. CA IX-IN-2 exhibits antitumor efficacy in mouse models .
hCAIX/XII-IN-5 (Coumarin 9a) a carbonicanhydrase (CA) inhibitor, and exhibits excellent hCA IX/XII selectivity (Ki=93.9 and 85.7 nM, respectively) over hCA I and hCA II. hCAIX/XII-IN-5 shows anti-proliferative activities to cancer cells. hCAIX/XII-IN-5 can delay cell cycle and induce apoptosis .
DPP IV/hCA II-IN-1 is a potent and selective dipeptidyl peptidase IV (DPP IV) and carbonicanhydrase (CA) inhibitor with an IC50 value of 0.049 μM for DPP IV and with Ki values of 0.0361, 0.0428, 0.0941, 0.1328, 0.2615, and 3.034 μM for CA II, CA VB, CA VA, CA IX, CA I, and CA IV, respectively .
FC11409B is an ureido-sulfamate carbonicanhydraseIX (CAIX) inhibitor. FC11409B inhibits proliferation and migration of breast cancer cell lines in both hypoxic (0.5% O2) and normoxic conditions (21% O2). FC11409B also inhibits 3D spheroid of breast cancer subtypes invasion. FC11409B is promising for research of breast and ovarian cancers .
WES-1 (Compound 8g) is an inhibitor of carbonicanhydraseIX (Ki: 55.9 μM). WES-1 has broad spectrum anti-proliferative activity against the cancer cells, such as leukemia (K-562 and MOLT-4), non-small cell lung cancer (NCI–H460), colon cancer (HCT 116 and HCT-15) and melanoma (LOX IMVI) cell lines .
4-(Chloromethyl)-7-hydroxycoumarin (compound 4) is a hydroxycoumarin derivative with potent antioxidant effect and high hydroxyl radical-scavenging property. 4-(Chloromethyl)-7-hydroxycoumarin contains a methyl group and a chlorine group in the heterocyclic ring. A series of coumarins incorporating hydroxy-, chloro- and/or chloromethyl-moieties has been investigated as potent inhibitors of the zinc enzyme carbonicanhydrase, expecially tumor-associated isoforms CA IX and XII .
hCAIX/XII-IN-13 is an inhibitor of human carbonicanhydrases (hCA). hCAIX/XII-IN-13 shows good inhibitory activity against the tumor-related CA subtypes IX and XII, with Ki values of 0.08 µM and 0.06 µM, respectively. Under hypoxic conditions, hCAIX/XII-IN-13 can restore the cytotoxicity of Doxorubicin (HY-15142A) on MCF-7 cells, increasing G2/M phase cell cycle arrest and apoptosis .
Chlorthalidone Impurity G (Chlorthalidone EP Impurity G) is a potential impurity found in commercial preparations of chlorthalidone with moderate antihypertensive effects. Chlorthalidone is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal tubule of the kidney, thereby preventing sodium and chloride reabsorption, resulting in decreased plasma volume and cardiac output. It also inhibits carbonicanhydrase (CA), including isoenzymes CAVB, VII, IX, XII, and XIII (Kis=2.8-23 nM) and to a lesser extent CAI, CAII, IV, VA, and VI (Ki=138-1,347 nM), mediating vasodilatory activity.
Antitumor agent-163 (Compound 3) is a photosensitizer used in Molecular-Targeted Photodynamic Therapy (MT-PDT) targeting carbonicanhydraseIX (CAIX). Antitumor agent-163 inactivates CAIX protein via singlet oxygen under 540 nm wavelength light, without affecting internal standard proteins such as α-tubulin, β-actin, and proliferating cell nuclear antigen (PCNA). Antitumor agent-163 induces cell membrane damage, inhibits cell viability (IC50 is 0.2 and 0.05 μM for A549 and U87MG). Antitumor agent-163 exhibits antitumor efficacy in mouse model .
hA2A/hCA XII modulator 1 (compound 14), a triazolopirazine, is a potent hA2A adenosine receptor (hA2AAR) antagonist with Kis of 6.4 nM, 4.819 μM, >30 μM for hA2AAR, hA1AR, hA3AR, respectively. hA2A/hCA XII modulator 1 is a potent human carbonicanhydrase XII (hCA XII) inhibitor with Kis of 6.2 nM, 46 nM, 466 nM, 8.351 μM for hCA XII, hCA II, hCA IX and hCA I, respectively. hA2A/hCA XII modulator 1 has the potential for cancer research .
GZ22-4 is a near-infrared (NIR) fluorescent probe. GZ22-4 shows high affinity for carbonicanhydraseIX (CAIX), with a Kd of 0.2 nM. GZ22-4 can be used for the research of visualize CAIX-positive tumors .
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonicanhydraseIX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). Carbonic Anhydrase 9 Protein, Human (Biotinylated, HEK293, Avi-His) is the recombinant human-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of Carbonic Anhydrase 9 Protein, Human (Biotinylated, HEK293, Avi-His) is 377 a.a., with molecular weight of ~60 kDa.
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). Carbonic Anhydrase 9 Protein, Human (HEK293, His) is the recombinant human-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Carbonic Anhydrase 9 Protein, Human (HEK293, His) is 377 a.a., with molecular weight of 45-60 kDa.
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). Carbonic Anhydrase 9 Protein, Canine (HEK293, His) is the recombinant canine-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-His labeled tag.
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). Carbonic Anhydrase 9 Protein, Human (HEK293, Fc) is the recombinant human-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Carbonic Anhydrase 9 Protein, Human (HEK293, Fc) is 377 a.a., with molecular weight of ~67.4 kDa.
Carbonic Anhydrase 9 Protein catalyzes the reversible hydration of carbon dioxide, essential for converting it to bicarbonate ions and protons, and vice versa. This enzymatic activity is crucial in physiological processes like acid-base balance regulation, respiration, and cellular pH homeostasis. Carbonic Anhydrase 9 Protein is vital for carbon dioxide transport and metabolism, contributing to overall regulation of its levels in the body. Carbonic Anhydrase 9 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-His labeled tag. The total length of Carbonic Anhydrase 9 Protein, Cynomolgus (HEK293, His) is 365 a.a., with molecular weight of 50-60 kDa.
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). Carbonic Anhydrase 9 Protein, Canine (HEK293, hFc) is the recombinant canine-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Carbonic Anhydrase 9 Protein, Canine (HEK293, hFc) is 373 a.a., with molecular weight of ~79 kDa.
The Carbonic Anhydrase 9 protein is responsible for catalyzing the interconversion between carbon dioxide and water, as well as facilitating the conversion of carbonic acid into its dissociated ions, namely bicarbonate and hydrogen ions. Carbonic Anhydrase 9 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-His labeled tag.
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). Carbonic Anhydrase 9 Protein, Human (HEK293, His-Avi) is the recombinant human-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of Carbonic Anhydrase 9 Protein, Human (HEK293, His-Avi) is 377 a.a., with molecular weight of 50-60 kDa.
Acetazolamide- 13C2,d3 is the 13C- and deuterium labeled Acetazolamide. Acetazolamide is a carbonicanhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX[1]. Diuretic effects[4].
CA9 Antibody (YA1368) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1368), targeting CA9. CA9 Antibody (YA1368) can be used for FC, ELISA experiment in human background.
Carbonic Anhydrase 9Rabbit mAb Antibody (YA2443) is a mouse-derived non-conjugated IgG antibody (Clone NO.: YA2443), targeting Carbonic Anhydrase 9. Carbonic Anhydrase 9 Antibody (YA2443) can be used for WB,IHC-P,FC experiment in human background.
Product Comparison
Compare
Clear All
Compare Products
Products
In-stock
-
+
Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample
YesNo
Size
* This product has been "discontinued".
Optimized version of product available:
/
In-stock
-
+
Add to Cart
Get quote
Inquiry Online
Your information is safe with us. * Required Fields.
